Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06716138 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration, sponsored by Avistone Biotechnology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 5
- Study locations
NCT06716138 is a Phase 1 study of Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration that is actively recruiting participants, run by Avistone Biotechnology Co.. The registered enrollment target is 96 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT06716138, a Phase 1 study of Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration, is actively recruiting participants, sponsored by Avistone Biotechnology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Interventions
- DRUG ANS03
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center - New York
Fujian
- Research Site - Fuzhou
Guangdong
- Research Site - Guangzhou
Shanghai Municipality
- Research Site - Shanghai
Sichuan
- Research Site - Chengdu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06716138
The ClinicalTrials.gov registry entry for NCT06716138 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avistone Biotechnology Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration appearing as the primary indexed condition, and to 1 intervention - of which ANS03 is the first listed.
NCT06716138 reports 5 study locations spanning 5 distinct geographic areas - top geographies include New York, Fujian, Guangdong.
Frequently Asked Questions
What is clinical trial NCT06716138 about?
NCT06716138 is a clinical study titled "A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
What is the current status of trial NCT06716138?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2025-03-06. Estimated completion is 2029-03-30.
What conditions does trial NCT06716138 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration.
What interventions are being tested in trial NCT06716138?
The interventions under investigation include: ANS03 (DRUG).
Who is sponsoring clinical trial NCT06716138?
This trial is sponsored by Avistone Biotechnology Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06716138 being conducted?
This trial has 5 study locations across New York, Fujian, Guangdong, Shanghai Municipality, Sichuan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.